UK regulators accused pharmaceutical companies Pfizer and Flynn of fraudulently overcharging the National Health Service (NHS) for critical anti-epilepsy medicines and exploiting their market dominance to boost prices overnight.
The Competition and Markets Authority (CMA) has reaffirmed its 2016 conclusion that the duo debranded the medication, Epanutin, to charge exorbitant rates for phenytoin sodium capsules.
The CMA began reevaluating the case when Pfizer filed an appeal against the CMA’s 2016 punishment of £84.2m, which was issued after the price paid to the NHS for the medication increased up to 2,600%.
Meanwhile, Flynn Pharma, a pharmaceutical distributor, was fined £5.2 million for charging exorbitant and unjust rates for phenytoin sodium capsules.
A spokesperson for Flynn Pharma said that the regulators’ provisional findings were “disappointing”.
The Flynn Pharma spokesperson also added that the firm has always claimed that the case was “fundamentally defective” and that the business had “not violated competition law or exploited any gap.”
According to a Pfizer spokeswoman, the company “continues to cooperate fully with the CMA’s ongoing inquiry.”
© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.